Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells

PURPOSE: Metformin, widely used as antidiabetic drug, showed antitumoral effects expecially in combination with chemotherapy. Our group recently has demonstrated that metformin and gefitinib are synergistic in LKB1-wild-type NSCLC cells. In these models, metformin as single agent induced an activati...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Corte, Carminia Maria, Ciaramella, Vincenza, Mauro, Concetta Di, Castellone, Maria Domenica, Papaccio, Federica, Fasano, Morena, Sasso, Ferdinando Carlo, Martinelli, Erika, Troiani, Teresa, De Vita, Ferdinando, Orditura, Michele, Bianco, Roberto, Ciardiello, Fortunato, Morgillo, Floriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://www.ncbi.nlm.nih.gov/pubmed/26673006
http://dx.doi.org/10.18632/oncotarget.6559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826204/
https://www.ncbi.nlm.nih.gov/pubmed/26673006
http://dx.doi.org/10.18632/oncotarget.6559

Ejemplares similares